Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

RemeGen Says HER2 ADC Paired with PD-1 Effective for Urothelial Carcinoma

publication date: Jun 6, 2023

RemeGen, a Yantai commercial-stage biotech, reported positive data from an early trial of its anti-HER2 ADC, disitamab vedotin, in combination with Junshi Bio’s PD-1 toripalimab for urothelial carcinoma. The combination met its safety endpoints and showed an Objective Response Rate of 73.2% and Complete Response of 9.8%. In 2021, disitamab vedotin was approved to launch in China for gastric cancer, the first China-developed ADC to be approved. Also in 2021, RemeGen out-licensed ex-Asia rights for the drug to Seattle’s Seagen in a $2.8 billion agreement. More details....

Stock Symbol: (HK: 9995; SHA: 688331)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital